Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma.
Antiplatelet
Aspirin
Asymptomatic carotid artery stenosis
Cardiovascular risk
Primary prevention
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
04
02
2020
accepted:
15
04
2020
pubmed:
15
5
2020
medline:
3
7
2021
entrez:
15
5
2020
Statut:
ppublish
Résumé
Carotid artery atherosclerosis (CAAS) is a common finding in asymptomatic subjects evaluated for cardiovascular (CV)-risk stratification. Besides the careful control of CV-risk factors, antithrombotic agents, and in particular aspirin, may be considered for primary prevention in patients at CV-risk. However, there is strong controversy on the use of aspirin in primary prevention. Even if several studies confirmed the association between CAAS and CV-events, CAAS is not universally recognized as an independent risk factor and the choice to use aspirin as primary prevention in these patients remains a medical dilemma. Here we review the available evidence on the prognostic value of asymptomatic CAAS for major CV-events and on the utility of antithrombotic agents in this population. We conclude that the detection of asymptomatic CAAS can not be considered as a direct indication to carry out primary prophylaxis with antithrombotic drugs, and the choice to use aspirin should be made only after the careful estimate of the individual's CV-and hemorrhagic risk.
Identifiants
pubmed: 32405817
doi: 10.1007/s11739-020-02347-7
pii: 10.1007/s11739-020-02347-7
doi:
Substances chimiques
Fibrinolytic Agents
0
Platelet Aggregation Inhibitors
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM